STOK

Stoke Therapeutics, Inc.

15.35 USD
-0.75 (-4.66%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Stoke Therapeutics, Inc. stock is up 36.44% since 30 days ago. The next earnings date is Aug 5, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 80% of the previous 4 May’s closed higher than April. In the last 10 Unusual Options Trades, there were 3 PUTs, 7 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
23 Apr 19:50 17 May, 2024 12.50 PUT 160 89
29 Apr 14:11 17 May, 2024 12.50 PUT 200 311
29 Apr 14:26 17 May, 2024 12.50 PUT 190 311
15 May 15:25 21 Jun, 2024 15.00 CALL 199 2
15 May 15:26 17 May, 2024 12.50 CALL 300 1062
16 May 17:15 16 Aug, 2024 5.00 CALL 75 256
16 May 17:24 15 Nov, 2024 2.50 CALL 25 85
17 May 14:14 16 Aug, 2024 5.00 CALL 48 256
17 May 15:00 15 Nov, 2024 2.50 CALL 25 73
20 May 17:08 21 Jun, 2024 15.00 CALL 200 207

About Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy.

  • Canaccord Genuity
    Tue May 7, 10:18
    buy
    confirm
  • HC Wainwright & Co.
    Tue May 7, 08:04
    buy
    confirm
  • Needham
    Mon May 6, 10:30
    buy
    confirm